Scholarlink

<p>Scalp cooling can prevent chemotherapy-induced alopecia in breast cancer patients. But data in gynecologic patients were scarce. The CHARM study was a single-center randomized study. Women planning for 3-weekly carboplatin and paclitaxel were randomized to either scalp cooling or usual clinical practice in 1:1 ratio. The primary endpoint was the efficacy in hair preservation after the completion of chemotherapy as assessed by the clinicians. Secondary endpoints included quality of life, the incidence of psychological distress, and safety. 142 women were invited to join the study but 56 refused. Finally, 44 women were randomized to the intervention group and 42 to the control group. The successful rate in preserving hair, defined as Dean score ≤ 2, upon completion of chemotherapy was significantly higher in the intervention group (29.6%, 95% confidence interval (CI) 12.4–46.9%) than the control group (0%, 95% CI 0–0%) (<i>p</i> = 0.002). Compared to the control group, the intervention group had significantly better global health status, physical functioning, and role functioning during the chemotherapy, lower incidence of psychological distress after cycle 2 of chemotherapy (27.8% vs. 62.2%, <i>p</i> = 0.003), and lower median PHQ-ADS scores after cycle 2 (5.5 vs. 11.0, <i>p</i> = 0.045) and 2–3&#xa0;weeks post-chemotherapy (5.0 vs. 9.0, <i>p</i> = 0.033). However, the intervention group had a 30% drop-out rate despite no major adverse events. Scalp cooling could reduce the incidence of CIA and potentially alleviate psychological distress and improve the QOL in gynecologic cancer patients. Further effort is needed to improve the acceptance and compliance rates in Asian population. (ClinicalTrials.gov number, NCT04168242).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Shuk Tak Kwok,
  • Lesley Suk Kwan Lau,
  • Tat On Chan,
  • Mandy Man Yee Chu,
  • Siew Fei Ngu,
  • Karen Kar Loen Chan,
  • Hextan Yuen Sheung Ngan,
  • Polly Pui Yee Ho,
  • Lina Wu,
  • Damaris Suk Mei Hung,
  • Heidi Ka Ying Lo,
  • Christina Sze Man Wong,
  • Ka Yu Tse

摘要

Scalp cooling can prevent chemotherapy-induced alopecia in breast cancer patients. But data in gynecologic patients were scarce. The CHARM study was a single-center randomized study. Women planning for 3-weekly carboplatin and paclitaxel were randomized to either scalp cooling or usual clinical practice in 1:1 ratio. The primary endpoint was the efficacy in hair preservation after the completion of chemotherapy as assessed by the clinicians. Secondary endpoints included quality of life, the incidence of psychological distress, and safety. 142 women were invited to join the study but 56 refused. Finally, 44 women were randomized to the intervention group and 42 to the control group. The successful rate in preserving hair, defined as Dean score ≤ 2, upon completion of chemotherapy was significantly higher in the intervention group (29.6%, 95% confidence interval (CI) 12.4–46.9%) than the control group (0%, 95% CI 0–0%) (p = 0.002). Compared to the control group, the intervention group had significantly better global health status, physical functioning, and role functioning during the chemotherapy, lower incidence of psychological distress after cycle 2 of chemotherapy (27.8% vs. 62.2%, p = 0.003), and lower median PHQ-ADS scores after cycle 2 (5.5 vs. 11.0, p = 0.045) and 2–3 weeks post-chemotherapy (5.0 vs. 9.0, p = 0.033). However, the intervention group had a 30% drop-out rate despite no major adverse events. Scalp cooling could reduce the incidence of CIA and potentially alleviate psychological distress and improve the QOL in gynecologic cancer patients. Further effort is needed to improve the acceptance and compliance rates in Asian population. (ClinicalTrials.gov number, NCT04168242).